Orchestra BioMed Holdings, Inc. (OBIO) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Orchestra BioMed reported revenue of $33.5M, up 1169.2% from $2.6M the year before. Net income was -$52.7M (a -157.4% net margin), or -$1.11 per diluted share. Gross margin was 99.4% and operating margin was -154.7%. Operating activities generated -$49.0M of cash, leaving -$49.5M of free cash flow. At fiscal year end, Orchestra BioMed held $114.9M in total assets against $51.5M in total liabilities, including $34.7M of cash and equivalents.
Open the full interactive Orchestra BioMed financials → Quarterly statements, key ratios, valuation history and price charts.
Orchestra BioMed Key Stats
| Share Price | $5.72 |
|---|---|
| Market Cap | $365.0M |
| 52-Week Range | $3.19 – $6.35 |
| Shares Outstanding | 63.8 million (basic, 2026 Q2) |
Orchestra BioMed Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.8M | $2.6M | $33.5M |
| Cost of Goods Sold | — | — | $54.3M | $66.9M | $85.3M |
| Gross Profit | — | — | $2.6M | $2.4M | $33.3M |
| Operating Income | -$394,756 | -$3.1M | -$51.5M | -$64.3M | -$51.8M |
| Pre-Tax Income | -$378,753 | -$2.7M | -$49.1M | -$61.0M | -$52.7M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$378,753 | -$2.7M | -$49.1M | -$61.0M | -$52.7M |
| Diluted EPS | -$0.02 | -$0.17 | -$1.48 | -$1.66 | -$1.11 |
Orchestra BioMed Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $861,000 | $30.9M | $110,000 | $88,000 |
| Net Income | -$20.8M | $6.2M | -$20.7M | -$23.8M |
| Diluted EPS | -$0.40 | $0.13 | -$0.33 | -$0.38 |
Orchestra BioMed Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.8M | $175,161 | $30.6M | $22.3M | $34.7M |
| Current Assets | $1.8M | $299,079 | $89.1M | $69.2M | $107.9M |
| Total Assets | $161.8M | $68.1M | $95.2M | $76.2M | $114.9M |
| Current Liabilities | $165,539 | $1.7M | $11.2M | $16.2M | $16.7M |
| Total Long-Term Debt | — | — | — | $15.0M | $15.0M |
| Total Liabilities | $5.8M | $7.3M | $27.2M | $43.2M | $51.5M |
| Shareholders' Equity | -$3.9M | -$6.9M | $68.0M | $33.0M | $53.6M |
Orchestra BioMed Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$272,362 | -$1.6M | -$46.1M | -$50.6M | -$49.0M |
| Cash From Investing | — | $92.6M | $10.7M | $13.1M | -$26.9M |
| Cash From Financing | — | -$92.6M | $46.2M | $29.2M | $88.3M |
| Free Cash Flow | — | — | -$46.2M | -$50.8M | -$49.5M |
Figures from Orchestra BioMed's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Orchestra BioMed financials page for every line item.
Orchestra BioMed Company Profile
| Ticker | OBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | New Hope, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001814114 |
Frequently Asked Questions
What was Orchestra BioMed's revenue in fiscal 2025?
Orchestra BioMed (OBIO) reported revenue of $33.5M for fiscal 2025.
What is Orchestra BioMed's annual revenue history?
Orchestra BioMed's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $2.8M; 2024: $2.6M; 2025: $33.5M.
What was Orchestra BioMed's net income in fiscal 2025?
Orchestra BioMed reported net income of -$52.7M for fiscal 2025.
What was Orchestra BioMed's earnings per share (EPS) in fiscal 2025?
Orchestra BioMed's diluted EPS was -$1.11 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Orchestra BioMed generate in fiscal 2025?
Orchestra BioMed generated -$49.5M of free cash flow in fiscal 2025.
What was Orchestra BioMed's revenue last quarter?
In its most recent reported quarter (2026 Q2), Orchestra BioMed reported revenue of $88,000.
How much debt does Orchestra BioMed have?
Orchestra BioMed reported $15.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Orchestra BioMed are outstanding?
Orchestra BioMed reported a weighted average of 63.8 million basic shares outstanding in 2026 Q2.
What is Orchestra BioMed's market cap?
Based on its latest closing price, Orchestra BioMed (OBIO) has a market capitalization of about $365.0M.
When does Orchestra BioMed's fiscal year end?
Orchestra BioMed's fiscal year end, as registered with the SEC, is December 31.
Where is Orchestra BioMed headquartered?
Orchestra BioMed lists its business address in New Hope, Pennsylvania in its SEC filings.